Tetralogic Pharmaceuticals Corp.
🇺🇸 Malvern, Pennsylvania, USAPharmaceuticals
Total raised
$28 M
5 rounds on record
Latest round
$5 M
Nov 2012
First round on record
Nov 2009
Today
Private
No later event on record
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2012 | $5 M | No. 5 | $2 to $10 million | debt, options | SEC | |
| May 2011 | $6 M | No. 4 | $2 to $10 million | equity | SEC | |
| Jul 2010 | $13 M | No. 3 | $10 to $50 million | equity | SEC | |
| Mar 2010 | $2 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Nov 2009 | $2 M | No. 1 | $2 to $10 million | debt, options | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Tetralogic Pharmaceuticals Corp. chose not to state its revenue in its newest notice of a funding round (Dec 2012).
SEC Form D · Dec 2012
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Dec 2012
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Amgen Inc | Company | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Amgen Ventures LLC | Venture capital | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Clarus Lifesciences II, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Clarus Ventures II GP, L.P. | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Clarus Ventures II, LLC | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| HealthCare Partners VII, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Healthcare Ventures VII LP | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David E. Weng | Executive officer | Dec 2012 |
| James E. Goldschmidt | Executive officer | Dec 2012 |
| John M. Gill | Executive officer | Dec 2012 |
| Helga A. Kautsky | Executive officer | May 2011 |
| Mark A. McKinlay | Executive officer | May 2011 |
| Andrew E. Pecora | Director | Dec 2012 |
| Brenda E. Gavin | Director | Dec 2012 |
| Douglas E. Onsi | Director | Dec 2012 |
| Douglas E. Reed | Director | Dec 2012 |
| James E. Woody | Director | Dec 2012 |
| John M. Gill | Director | Dec 2012 |
| Michael E. Steinmetz | Director | Dec 2012 |
| Paul E. Schmitt | Director | Dec 2012 |
| Andrew A. Pecora | Director | May 2011 |
| Brenda A. Gavin | Director | May 2011 |
| Douglas A. Reed | Director | May 2011 |
| Harold A. Werner | Director | May 2011 |
| James A. Woody | Director | May 2011 |
| Michael A. Steinmetz | Director | May 2011 |
| Paul A. Schmitt | Director | May 2011 |
| George A. McLendon | Director | Mar 2010 |
| Jack A. Lasersohn | Director | Mar 2010 |
| Jim A. Woody | Director | Mar 2010 |